Acute coronary syndrome induced by capecitabine therapy.
Capecitabine, a new member of the fluoropyrimidine family, is an orally administered drug that delivers fluorouracil (5-FU) selectively to the tumour. Although the cardiotoxicity of 5-FU is well documented, there is little published data about cardiovascular adverse effects of Capecitabine. This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.
Wijesinghe
Namal
N
Waikato Hospital, Cardiology Department, Private Bag 3200, Hamilton 2001, New Zealand. namalw@gmail.com
Thompson
Paul I
PI
McAlister
Hugh
H
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D000069287:Capecitabine; D003110:Colonic Neoplasms / Q000188:drug therapy; D017023:Coronary Angiography; D003327:Coronary Disease / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000503:physiopathology; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D011355:Prodrugs
D000964:Antimetabolites, Antineoplastic; D011355:Prodrugs; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil